Skip to main content

Emerging agents and regimens for cancer therapy 2020

Call for papers

This Journal of Hematology & Oncology collection is the 2020 version of an annual series on emerging agents and regimens for cancer therapy.

The collection is currently open for submissions. Interested authors should submit their abstract to the journal's Editorial Office.

Research and review papers on novel agents, first-in-human clinical trials, and regimens for different cancer types will be considered. For published articles in "Emerging agents and regimens for cancer therapy 2019," see here.


  1. Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous s...

    Authors: Walter Hanel and Narendranath Epperla

    Citation: Journal of Hematology & Oncology 2020 13:79

    Content type: Review

    Published on:

  2. Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognosti...

    Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian and Nicholas J. Short

    Citation: Journal of Hematology & Oncology 2020 13:70

    Content type: Review

    Published on:

  3. Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

    Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2020 13:64

    Content type: Review

    Published on:

  4. Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

    Authors: Nancy G. Azizian and Yulin Li

    Citation: Journal of Hematology & Oncology 2020 13:61

    Content type: Review

    Published on:

  5. Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

    Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng

    Citation: Journal of Hematology & Oncology 2020 13:60

    Content type: Review

    Published on: